Olanrewaju Okusanya

9PUBLICATIONS
66CO-AUTHORS
ChemotherapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Toxicology (incl. clinical toxicology)Molecular medicine
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Oct 02, 2025
FDA-AACR Strategies for Optimizing Dosages for Oncology Drug Products: Early-Phase Trials Using Innovative Trial Designs and Biomarkers.

Olanrewaju O Okusanya, Gabriela I Patilea-Vrana, Anthony Sireci

|Jul 01, 2025
FDA Approval Summary: Ivosidenib for Treatment of Adult Patients with Relapsed/Refractory Myelodysplastic Syndrome with an IDH1 Mutation.

Ashley C Woods, E Dianne Pulte, Xin Wang

|Jun 05, 2025
Using Quantitative Approaches to Optimize Dosages for New Combinations and Subsequent Indications for Oncology Drugs.

Wei Gao, Jiang Liu, Cynthia J Musante

|May 28, 2025
FDA Approval Summary: Abatacept for the Prophylaxis of Acute GVHD.

Kelly J Norsworthy, Donna R Rivera, Joseph Wynne

|Oct 30, 2024
FDA Approval Summary: Olutasidenib for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase 1 Mutation.

Ashley C Woods, Kelly J Norsworthy, Moran Choe

|Jan 18, 2024
Clinical Pharmacology Approaches to Support Approval of New Routes of Administration for Therapeutic Proteins.

Yow-Ming C Wang, Ping Ji, Sudharshan Hariharan

Pageof 2

Frequent Collaborators

5 joint publications

Kelly J Norsworthy

4 joint publications

Jonathon Vallejo

4 joint publications

R Angelo de Claro

3 joint publications

Richard Pazdur